Agios Pharmaceuticals (AGIO) Interest & Investment Income (2012 - 2026)

Agios Pharmaceuticals has reported Interest & Investment Income for 15 years, with the latest figure at $10.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 32.9% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2026 stood at $51.1 million (down 7.59% YoY), and the FY2025 full-year result was $56.4 million, up 17.25% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $10.8 million, down from $12.4 million in the prior quarter.
• The five-year high for Interest & Investment Income was $18.0 million in Q4 2024, with the low at $694000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $9.5 million across 5 years, with a median of $8.6 million in 2023.
• Annual changes were most pronounced in 2022 — Interest & Investment Income surged 2048.91% — and 2026, when it plunged 32.9%.
• Agios Pharmaceuticals' Interest & Investment Income stood at $6.5 million in 2022, then jumped by 32.92% to $8.6 million in 2023, then jumped by 108.89% to $18.0 million in 2024, then tumbled by 31.11% to $12.4 million in 2025, then fell by 13.01% to $10.8 million in 2026.
• The last three Interest & Investment Income figures came in at $10.8 million (Q1 2026), $12.4 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.